India, May 7 -- Theriva Biologics (TOVX), Wednesday reported positive topline results from the VIRAGE Phase 2b study evaluating the company's lead drug candidate VCN-01 plus standard-of-care chemotherapy gemcitabine/nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
The study met its primary safety endpoint as VCN-01 was well-tolerated, with transient and reversible adverse events. The company's shares were more than 45% up in pre-market.
In the study, 96 newly-diagnosed metastatic PDAC patients were randomized to receive either VCN-01 plus standard-of-care gemcitabine/nab-paclitaxel or gemcitabine/nab-paclitaxel alone.
Data from the study showed that 48 patients treated with at least one dose of gemcitab...